Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Open-Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of YL-13027 in Patients With Advanced Solid Tumors

Next Previous
Trial Profile

A Multi-Center, Open-Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of YL-13027 in Patients With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs YL 13027 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Shanghai Yingli Pharmaceutical

Most Recent Events

  • 26 May 2022 According to Yingli Pharma media release, first patient dosed in this trial and this trial is being conducted in collaboration with The University of Texas MD Anderson Cancer Center and 4 clinical centers in the US.
  • 16 May 2022 Status changed from not yet recruiting to recruiting.
  • 11 Feb 2022 New source identified and integrated ClinicalTrials.gov: (US National Institutes of Health: NCT05228600).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top